BARCELONA, Spain & WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European Hematology Association (EHA) meeting being held June 10-13, 2010 in Barcelona, Spain.
